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ABSTRACT  
BACKGROUND:   The   aim   of   the   study   was   to   assess   whether   African   subjects   with  
fragility  fractures  were  being  identified  for  assessment  for  osteoporosis  on  presentation  to  
the   orthopaedic   department   at   Chris   Hani   Baragwanath   Academic  Hospital   (CHBAH)   in  
Soweto.   In   addition,   the   recommendation   for   secondary   prevention   of   disease   for   these  
subjects,  was  also  assessed.    
METHOD:  One  hundred  African  subjects  over   the  age  of  50  years  with   fragility   fractures  
were   identified   in   the   orthopaedic   wards   and   clinics   at   CHBAH.   These   subjects   were  
interviewed   with   two   separate   questionnaires   addressing   risk   factors   and   education  
regarding   osteoporosis,   and   whether   further   management   was   suggested.   The   first  
interview  was  conducted   in  June  and  July  2015.  After  18  months,  a   follow  up   telephonic  
interview  was  conducted,  in  December  2016,  with  37  of  the  original  100  subjects.    
RESULTS:  Of   the  100  subjects  evaluated,  89   (89%)  were  asked  at   least  one  screening  
question.  The  most  frequently  asked  question  about  risk  factors  for  osteoporosis  in  the  first  
interview,   was   regarding   previous   fractures   and   was   asked   of   61   (61%)   of   the   100  
subjects.  A  further  37  (37%)  of  all  subjects  had  been  given  advice  regarding  appropriate  
bone  strengthening  exercises  to  prevent  osteoporosis.  Only  five  subjects  (5%)  were  asked  
to   return   for   further   assessment.   The   second   interview   showed   that   the  most   frequently  
asked  question  was  regarding  previous  fractures  in  24  (64.9%)  of  the  37  subjects  and  18  
(48.6%)  of  the  37  subjects  had  been  advised  to  do  bone  strengthening  exercises.  Only  two  
(5.4%)  new  subjects  could  confirm  receiving  a  date  to  return  for  assessment.    
CONCLUSION:   In   this   study,   orthopaedic   surgeons   were   proven   to   be   inadequately  
assessing  risk  factors  for  osteoporosis  and  were  infrequently  referring  patients  for  therapy.  
Orthopedic  surgeons  are  often  the  only  practitioners  to  see  patients  with  fragility  fractures  
and   thus   they  have  a  crucial   role   in   identifying  and  appropriately   referring   these  patients  
for  further  investigations  and  medical  management  for  osteoporosis.    
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CHAPTER  1:  INTRODUCTION  
1.1  BACKGROUND  
Osteoporosis   is   the  most  common  bone  disease   in  humans  and   is  defined  by   the  World  
Health   Organisation   (WHO)   as   a   systemic   skeletal   disease   characterized   by   ‘low   bone  
mass   and  microarchitectural   deterioration   of   bone   tissue  with   a   consequent   increase   in  
bone  fragility  and  susceptibility  to  fracture’.  (1-­2)    
  
The  criteria  for  diagnosis  of  osteoporosis  are  based  on  a  history  or  evidence  of  a  fragility  
fracture  or  by  measuring  a  low  bone  mineral  density  (BMD).  (1)  The  BMD  criteria  for  the  
diagnosis  of  osteoporosis,  according  to  the  WHO,  are  by  confirming  a  BMD  measurement  
at  the  hip  or   lumbar  spine  that   is   less  than  or  equal  to  2.5  standard  deviations  below  the  
mean  BMD  of  a  young  adult   reference  population.   (1)  The   risk  of   fractures   is  highest   in  
those  with  the  lowest  BMD.  (1)  The  latest  WHO  guideline  recommends  using  the  femoral  
neck  as  a  single  reference  site  for  the  diagnosis  of  osteoporosis.  (2)      
 
Fragility   fractures   are   defined   as   fractures   that   are   caused   by   injury   that   would   be  
insufficient   to   fracture  a  healthy  bone.  (3)  The  WHO  classifies   fragility   fractures  as  those  
that  occur  as  a  result  of  minimal  trauma  such  as  a  fall  from  a  standing  height  or  less,  or  no  
identifiable   trauma.  (3)  Typical   fragility   fractures   include  vertebral   (spine),  proximal   femur  
(hip)  and  distal   forearm  (wrist)  however   they  may  also  occur   in  other  bones  such  as   the  
proximal  humerus,  pelvis  and  ribs.  (2-­3)  
  
1.2  DEMOGRAPHICS  OF  PATIENTS  WITH  OSTEOPOROSIS  
Fracture  risk  increases  two  to  fivefold  in  the  elderly  as  compared  to  the  young,  regardless  
of  BMD  measurements.   (4)  Postmenopausal  women  are  at   increased   risk   of   bone   loss.    
(4)  Females  sustain  fractures  more  frequently  than  males.  (4)  Bone  loss  in  men  starts  later  
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and  progresses  at  a  slower   rate  however,  by   the  age  of  65  years  both  men  and  women  
have  an  equal  and  steady  rate  of  bone  loss.  (5)  Approximately  20%  of  men  over  the  age  of  
50  years  are  at  risk  of  having  osteoporosis  related  fracture.  (1)  
  
The  prevalence  of  osteoporosis  varies  amongst  ethnic  groups.  (6-­7)  The  reasons  for  this  
are   differing   BMD,   genetic   predisposition,   inherent   skeletal   structural   differences,   bone  
turnover   rate   variability   and   electrolyte   and   mineral   homeostasis   changes.   (6)   Body  
composition,  weight,  gonadal  hormone  deficiencies  and  social  status  also  contribute  to  the  
heterogeneity.  (7)    
  
1.3  BONE  STRUCTURE  AND  PHYSIOLOGY  
The  long  bones  are  composed  of  a  hollow  shaft  (diaphysis),  a  flared  metaphysis  below  the  
growth   plates;;   and   rounded   epiphysis   above   the   growth   plates.   (8)   The   diaphysis   is  
composed   primarily   of   dense   cortical   bone,   whereas   the  metaphysis   and   epiphysis   are  
composed  of  trabecular  meshwork  bone  surrounded  by  a  thin  layer  of  dense  cortical  bone.  
(8)  
  
Cortical   bone   is   dense   and   surrounds   the   marrow   space,   whereas   trabecular   bone   is  
composed  of  a  honeycomb-­like  network  of  trabecular  plates  and  rods  interspersed  in  the  
bone  marrow  compartment.  (8)  
  
Different  bones  and  skeletal   sites  have  different   ratios  of   cortical   to   trabecular  bone.   (8)  
The  vertebrae  are  composed  of  cortical  to  trabecular  bone  in  a  ratio  of  25:75.  This  ratio  is  
50:50  in  the  femoral  head  and  95:5  in  the  radial  diaphysis.  (8)  
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Bone  remodeling  is  the  process  by  which  bone  is  renewed  to  maintain  bone  strength  and  
mineral   homeostasis.   (8)  Bone   remodeling   is   regulated  by  osteoclasts   that   resorb  bone,  
and  osteoblasts  that  are  involved  in  the  formation  of  new  bone.  (8-­9)  Osteoblasts  secrete  
the   components   of   the   bone   matrix   including   collagen   and   proteoglycans   that   give   the  
bones   their   tensile   strength,   and   the   tight   binding  with   deposition  of   bone   salts   give   the  
bones  shear  strength.  (9)  Osteoclasts  express  receptor  activator  of  nuclear  factor  kappa-­B  
(RANK)   receptors   which,   when   physiologically   stimulated,   cause   an   increase   in   bone  
resorption.  (9)    
  
Metabolic   functions  of   the  bone  are  controlled  by   two  main  calcium  regulating  hormones  
namely   the   parathyroid   hormone   (PTH)   and   1,25   dihydroxycholecalciferol   vitamin   D3  
[1.25(OH)2D3].  (8-­9)  Calcitonin  is  a  third  hormone  that  can  inhibit  bone  resorption  but  only  
plays  a  small  role  in  physiological  calcium  regulation.  (4)  PTH  increases  the  serum  calcium  
level  by  its  action  on  the  bone,  kidney  and  intestine  and  stimulates  the  production  of  active  
vitamin  D  by  the  kidney.  (8-­9)  
  
Calcium   and   phosphate   salts   have   an   intrinsic   attraction   to   the   bone   matrix   and   are  
subsequently   converted   to  hydroxyapatite   [Ca10(PO4)6(OH)2],   the  main  crystalline  salt  of  
the  bone.  (8-­9)  Hydroxyapatite  gives  bone  its  compressional  strength.  (8)  Other  hormones  
such  as  growth  hormone,   insulin-­like  growth   factor   (IGF),  glucocorticoids,  oestrogen  and  
thyroid  hormones  can  also  regulate  skeletal  growth  or  loss.  (8)  
  
1.4  BONE  STRUCTURE  AND  PHYSIOLOGY  IN  OSTEOPOROSIS  
Bone   loss   by   resorption   is   controlled   by   an   interaction   between   osteoblasts   and  
osteoclasts.  Osteoblasts  are  the  primary  regulators  of  bone  formation  and  osteoclasts  are  
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mainly   responsible   for  absorption.   (6,8)  Compared   to  normal  bone,   the  microarchitecture  
of  the  bone  in  osteoporosis  is  severely  compromised  due  to  bone  degradation.  (10)    
  
Osteoclast   recruitment   from   hematopoietic   cells   is   affected   by   the   expression   of   an  
osteoclast   differentiation   factor   known   as   receptor   activator   of   nuclear   factor   kappa-­B  
ligand   (RANK-­L).   (6)   RANK-­L   binds   to   a   RANK   receptor   located   on   the   surface   of  
osteoclast   precursors   to   initiate   osteoclastogenesis.   (6)   Osteoblasts   also   produce  
macrophage   colony   stimulating   factor   (M-­CSF)   which   enhances   the   replication   of  
osteoclast   precursors   via   action   on   the   c-­fms   receptor.   (6)   Cytokines   such   as   tumour  
necrosis   factor   (TNF),   prostaglandin   E2,   interleukin   (IL)   1   and   6   also   promote   bone  
resorption  by  elongating  the  lifespan  of  the  osteoclast.  (6)  
  
Peak  bone  mass  is  reached  in  the  third  decade  of  life  and  is  influenced  by  genetic  factors,  
nutrition,   endocrine   status   and   physical   activity.   (1)  Reasons   for   having   low   bone  mass  
include   failure   to   reach   optimal   peak   bone   mass   or   an   increased   loss   of   bone   after  
achieving  peak  bone  mass,  or  an  inability  to  replace  lost  bone.  (6)  This  can  be  influenced  
by  genetic  and  environmental  factors  and  by  different  hormones,  for  instance,  a  deficiency  
of   oestrogen.   (6)   Oestrogen   deficiency   is   a   major   factor   associated   with   increased  
resorption  of  bone  in  women,  resulting  in  aggressive  osteoclastic  activity  and  a  decreased  
ability  of  osteoblasts  to  form  new  bone.  (6)  In  older  men,  a  decline  in  bone  mineral  density  
(BMD)  is  noted  to  be  due  to  oestrogen  deficiency  rather  than  testosterone  deficiency.  (11)  
An   excess   of   PTH,   resulting   from   decreased   absorption   of   calcium   and   decreased  
production  of  active  vitamin  D,  also  contributes  to  bone  loss  by  interacting  with  osteoclastic  
promoting   receptors  on   the  osteoblastic   cells  and  enhancing  expression  of   the  RANK-­L.  
(6,11)  
  
  5 
Circulating   insulin-­like   growth   factor   one   (IGF-­1)   level   decreases   with   age,   and   an  
association   between   osteoporosis   and   low   IGF-­1   has   been   documented.   (6)  Decreased  
BMD  has  been  noted   in  patients  with   type   I  diabetes  mellitus  and  a  normal   to   increased  
BMD   has   been   noted   in   insulin   resistance   states   with   increased   circulating   insulin.   (6)  
Glucocorticoids   inhibit   bone   formation   via   its   effect   on   osteoblast   proliferation   and  
osteoblast   survival.   (6)   Lastly,   polymorphisms   in   the   genes   that   encode   collagen,   the  
oestrogen  receptor,  interleukin-­6  (IL-­6)  and  the  vitamin  D  receptor  have  also  been  shown  
to  play  a  role  in  BMD  regulation.  (6)  
  
1.5  CLASSIFICATION  OF  OSTEOPOROSIS  
Causes   of   osteoporosis   can   be   divided   into   primary   and   secondary.   (12)   Primary  
osteoporosis  is  divided  into  type  1  and  type  2  and  is  age-­related.  Secondary  osteoporosis  
is  classified  as  type  3.  (12)  Type  1  disease  occurs  in  5  to  20%  of  postmenopausal  women.  
(12)  This  type  of  osteoporosis  is  thought  to  be  due  to  a  deficiency  in  oestrogen  resulting  in  
resorption  of  calcium  from  the  bone  due  to  the  heightened  action  of  parathyroid  hormone  
on  the  bone.  (12)  Type  2  primary  osteoporosis  is  prevalent  in  patients  over  the  age  of  70  
and   is   due   to   the   decreased   production   of   one   alpha,   25   dihydroxycholecalciferol  
[1,25(OH)2D3]  from  the  kidney  resulting  in  a  decrease  in  calcium  absorption.  (12)  Due  to  
decreased  calcium  levels,  the  level  of  PTH  increases  and  bone  resorption  ensues.  (12)  
  
Secondary   causes   of   osteoporosis   may   be   found   in   up   to   30%   of   patients   with  
osteoporosis  especially  premenopausal  women,  men  with  osteoporosis  and  patients  with  
hip  fractures.  (13)  There  are  multiple  causes  of  secondary  osteoporosis  and  these  include  
endocrine   disorders   such   as   diabetes   and   hyperthyroidism,   eating   disorders,   marrow-­
related  disease,   gastrointestinal   and  bile   tract   abnormalities,   chronic   renal   diseases  and  
malignancies.   (14)   Common   medical   conditions   such   as   chronic   obstructive   airway  
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disease  and   rheumatoid  arthritis   also   contribute   to   the  development  of   osteoporosis.   (4)  
Anticonvulsants,  corticosteroids,  anticoagulants  and  aromatase  inhibitors  are  just  a  few  of  
the  numerous  drugs   that  have  also  been   implicated   in   the  development  of  osteoporosis.  
(4,14,15)  
  
1.6  RISK  FACTORS  FOR  OSTEOPOROSIS    
There   are  multiple   risk   factors   for   osteoporosis,   the  major   factors   being   advanced   age,  
previous   fragility   fracture,   body   mass   index   (BMI)   below   18   and   a   family   history   of  
osteoporotic  fractures.  (4)  Other  risk  factors  identified  include  smoking,  excessive  alcohol  
intake   (three   or   more   units   per   day),   glucocorticoid   intake,   hypogonadism,   inadequate  
calcium  and  vitamin  D  intake,  sedentary  lifestyle  (i.e.  less  than  30  minutes  a  day,  for  two  to  
three   days   of   the   week,   of   weight   bearing   and   muscle   strengthening   exercises),   high  
propensity   to   fall,  genetic  and  ethnic   factors  and  certain  systemic   inflammatory  diseases  
known  to  affect  bone  adversely  such  as  rheumatoid  arthritis.  (4,15)  Factors  that  influence  
bone  quality  such  as  rate  of  bone  remodeling,  collagen  and  mineral  distribution,  porosity  of  
the  cortex  and  shape  of  the  trabeculae  within  the  bone,  are  not  easy  to  determine.  (16)  For  
this  reason,  risk  factors  for  fractures  are  used  as  surrogate  markers  of  bone  strength.  (16)  
  
Risk   factors   for   fragility   fractures   and   for   osteoporosis   are   similar.  However,   risk   factors  
specific   to   fragility   fractures   include   gender,   nutrient   malabsorption   and   high   caffeine  
intake.  (17)  Reduced  bone  density  is  a  major  risk  for  fragility  fracture.  (18)  A  prior  fragility  
fracture  after   the  age  of  40  years   is  associated  with  a  1.5   to  9.5   fold   increased  risk  of  a  
future  fracture.  (18)    
  
The   majority   of   men   have   at   least   one   secondary   cause   for   osteoporosis. (5) The   risk  
factors   for   secondary  osteoporosis   that  are  associated  with  osteoporosis   in  men   include  
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hypogonadism,   smoking,   alcohol   abuse,   use   of   glucocorticoids,   chronic   diseases   of   the  
kidneys,  gastrointestinal  tract,  immobilisation  and  low  calcium  intake.  (5)  
  
Due   to   the   high   prevalence   of   treatment-­naive   human   immunodeficiency   virus   (HIV)  
infected   people   in   South   Africa,   it   was   initially   thought   that   this  would   be   a   contributing  
factor  to  decreased  bone  mass,  however  this  has  not  been  conclusively  proven.  (19)  
  
1.7  INCIDENCE  AND  ECONOMIC  BURDEN  
Approximately  10  million  adults  suffer  from  osteoporosis  in  the  United  States  (US).  (20)  In  
the   year   2000   it   was   estimated   that   nine   million   osteoporotic   fractures   occur   annually  
worldwide,  of  which  1.6  million  were  at   the  hip,  1.7  million  at   the  forearm  and  1.4  million  
were   vertebral   fractures.   (15,21)   Every   year   osteoporotic   fractures   resulted   in   432,000  
hospital   admissions,   2.5   million   medical   office   visits,   and   180,000   nursing   home  
admissions   in   the   US.   (1)   The   percentage   of   patients   with   osteoporosis   is   known   to  
increase  progressively  with  age.   (16,20,22)  Women   in  Europe  over   the  age  of  45  spend  
more   days   in   hospital   due   to   osteoporosis   than   patients   with   diabetes   mellitus   or  
myocardial  infarctions.  (22)  The  number  of  patients  with  fragility  fractures  is  also  projected  
to  increase  and  it  is  predicted  that  every  third  man  and  every  second  woman  over  the  age  
of  60  will  experience  at  least  one  fragility  fracture  in  their  lifetime.  (23)    
  
The  present  population   in  South  Africa   (SA)   is  estimated   to  be  approximately  50  million.  
(24)  It   is  estimated  that  around  1.4  million  females  aged  over  50  years  and  60000  males  
aged  over  50  years,  are  suffering  from  osteoporosis  in  SA.  (24)  This  data  is  extrapolated  
from   international  data  and  may  not  be  considering  ethnic  differences   in  our  population.  
Due  to  the  rapidly  ageing  population  in  Africa,   the  burden  of  osteoporotic  hip  fractures   is  
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expected   to   rise.   (25)  By   the   year   2050   out   of   6  million   predicted   hip   fractures,   70%  of  
these  fractures  are  predicted  to  occur  in  Africa,  Asia  and  Latin  America.  (25)  
  
In  Africa,  Egypt  has  statistics  regarding  bone  disease:  53.9%  of  postmenopausal  women  
have   osteopenia   while   28.4%   have   osteoporosis.   (15)   In   both   Cameroon   and   Morocco  
patients  with   hip   fractures  due   to   osteoporosis  were   identified  however   the   fracture   rate  
was  low  when  compared  to  the  US.  (25)  
  
An  increase  in  the  number  of  patients  with  fragility  fractures  comes  with  an  increase  in  the  
economic   burden   to   society.   In   the   United   Kingdom   (UK)   cost   for   osteoporotic   care   is  
estimated  at  two  billion  pounds  per  year.  (26)  In  the  countries  forming  part  of  the  European  
union,  osteoporotic  fractures  have  accounted  for  37  billion  Euros  being  spent  and  the  loss  
of  1,180,000  quality  adjusted  life  years  just   in  the  year  2010.  (21)  Global  cost  of  care  for  
osteoporosis  is  set  to  increase  by  25%  from  the  year  2010  to  2025.  (21)  
  
Few  studies  have  been  done  documenting  the  economic  burden  of  osteopenia  and  fragility  
fractures.  A  study  done  in  Mexico  has  shown  a  cost  of  $154.9  million  for  both  osteoporosis  
and  osteopenia.  (27)  Costs  due  to  fragility  fractures  were  $256.2  million  for  the  year  2010  
alone.  (27)  By  the  years  2015  and  2025  this  amount  has  been  estimated  to  be  19.2%  and  
41.7%  higher  respectively.  (27)  In  SA  currently,  the  acute  cost  of  treating  a  hip  fracture  is  
R150000.  (25)  
  
1.8  PREDICTING  FRACTURES  
More   than  half   of   fragility   fractures   occur   in   patients   that   do   not   have  osteoporosis  with  
BMD   criteria.   (28)   Limitations   to   diagnosis   of   osteoporosis   using   WHO   criteria   alone  
include   a   decreased   sensitivity   to   predict   fracture   risk   by   using   a   single   BMD  
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measurement,  the  use  of  the  same  criteria  to  assess  patients  of  various  races,  ages  and  
genders  and   that  extra  skeletal   risk   factors  such  as  propensity   to   falls,  decreased  vision  
and  presence  of  other  systemic  diseases,  are  not  considered.   (4)  Consequently,  a  more  
accurate   way   to   assess   for   future   fracture   risk   in   patients   would   be   to   combine   BMD  
measurements  with  identification  of  clinical  risk  factors,  assessment  of  bone  turnover  using  
biochemistry   or   bone   histology   and   the   results   of   various   bone   specific   radiological  
investigations.  (4)    
  
Clinical  risk  factors  (CRF)  for  osteoporosis  have  been  used  to  identify  patients  who  require  
BMD  testing  and  to  assess  fracture  risk  so  as  to  decide  on  future  treatment  options.  (4,16)  
CRFs   identified   by  WHO   in   the  WHO  Technical  Report   assessing  10-­year   risk   of  major  
osteoporosis-­related  fracture  of  the  hip,  spine,  forearm  and  humerus  include  age,  gender,  
prior   fragility   fractures,   family  history  of  hip  fracture,   low  BMI,  use  of  oral  glucocorticoids,  
smoking,   excess   alcohol   intake,   secondary   osteoporosis   and   rheumatoid   arthritis.   (4)  
CRFs  differ  in  importance  in  different  population  groups  and  thus  must  be  researched  and  
validated  in  these  populations.  (4,7)    
  
The  Fracture  Risk  Assessment  Tool  (FRAX)  has  been  developed  by  the  WHO  to  calculate  
the   10-­year   probability   of   a   major   osteoporotic   fracture   taking   into   account   clinical   risk  
factors  and  femoral  neck  BMD.  (1,22)   It  can  also  be  calculated  without   the  femoral  neck  
BMD  value  if  this  is  not  available.  This  tool  is  available  online  and  is  validated  for  several  
countries.   (13)  FRAX   is   the  most   frequently   recommended   tool   followed  by  QFracture   in  
the   UK,   Canadian   Association   of   Radiologists   and   Osteoporosis   Canada   (CAROC)   in  
Canada   and   Garvan   in   Australia.   (17,28)   None   of   the   fracture   assessment   tools   were  
found  to  perform  better  than  the  others  and  simple  tools  were  found  to  be  just  as  good  as  
complex  ones.  (17,28)  Unfortunately  comparisons  of  the  tools  in  similar  populations  were  
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never  carried  out  therefore  firm  conclusions,  regarding  the  comparison  between  the  tools,  
could  not  be  made.  (28)  
  
FRAX  is  intended  for  use  in  postmenopausal  women  and  male  patients  above  the  age  of  
50.   (1)   Treatment   decisions   should   be   based   on   fracture   probability   using   FRAX.   (28)  
FRAX  has  however  not  been  validated  for  patients  who  are  currently  or  were  previously  on  
treatment  for  osteoporosis  nor  in  patients  with  secondary  causes  of  osteoporosis.  (1)    
  
The  value  of  the  fracture  risk  assessment  is  not  universally  recognised  as  many  criticisms  
have  been  made,  including  the  necessity  of  internet  access,  variations  in  BMI  and  mortality  
across   various   ethnicities   and   the   exclusion   of   variables   such   as   falls.   (28)   FRAX  
underestimates  fracture  risk  in  patients  with  recent  fractures,  multiple  osteoporosis  related  
fractures  and  those  who  are  at  an  increased  risk  of  falling.  (1)  The  use  of  FRAX  in  patients  
with   low   BMD   at   the   lumbar   spine   and   normal   BMD   at   the   femoral   neck   also  
underestimates  the  fracture  risk  in  these  patients.  (1)  
  
Identification   of   CRFs   in   patients   is   valuable   in   case   finding   and   is   probably   more  
attainable   than   screening   a   population   at   risk   with   dual   energy   x-­ray   absorptiometry  
(DEXA).   (4,28)  Patients  with   fragility   fractures  often  do  not  have  BMD  measurements   in  
keeping  with   the  criteria   for   the  diagnosis  of  osteoporosis.   (28)  Approximately  50%  have  
low  bone  mass  or  osteopenia  on  DEXA.  (28)  Assessing  for  CRFs  in  these  patients  would  
ensure  appropriate  referral   for   further   investigations  and  would  also  assist  with  choice  of  
pharmacotherapy.  (3,28)  A  study  done  by  Hegeman  et  al  screened  100  patients  with  low  
trauma  fractures  in  their  fracture  and  osteoporosis  clinic  and  found  only  67%  to  have  BMD  
criteria  for  osteoporosis.  (29)  The  remaining  20%  of  the  patients  had  osteopenia  and  13%  
had  normal  DEXA  scans.  (29)  
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The  British  Orthopaedic  Association  (BOA)  guidelines  recommend  that  all  patients  above  
the  age  of  60  years  with  a   fragility   fracture  be  evaluated  by  a  DEXA  scan,  and  patients  
younger  than  60  years  old  with  fragility  fractures  should  be  assessed  for  the  presence  of  
risk  factors  for  osteoporosis  and  scanned  only  if  these  risk  factors  are  present.  (26)    
  
Patients  in  whom  BMD  testing  should  be  considered,  according  to  the  United  States  (US)  
National  Osteoporosis  Foundation  (NOF)  include  1)  women  over  the  age  of  65  years  and  
men  over  the  age  of  70  years  regardless  of  their  clinical  risk  factors  2)  adults  who  have  a  
fracture  at  or  after  the  age  of  50  years  3)  younger  postmenopausal  women,  menopausal  
woman  and  men  between  the  ages  of  50  and  69  years  old  with  clinical  risk  factors  and  4)  
patients  with  a  systemic  disease  or  on  medication  associated  with  bone  loss.  (1)  
  
The   National   Osteoporosis   Foundation   of   South   Africa   (NOFSA)   guidelines   differ   and  
suggest  bone  mass  measurement  in  women  aged  65  years  and  older  and  in  men  over  the  
age  of  70  years.  (4)  Bone  mass  measurement  should  also  be  done  in  patients  with  known  
secondary  causes  of  osteoporosis,  a  history  of  fragility  fractures  after  the  age  of  40  years,  
radiographic   evidence   of   vertebral   fractures   or   osteopenia,   to   facilitate   a   decision  
regarding   initiation  or  cessation  of  a  drug  and   if   there   is  a  presence  of  major  clinical  risk  
factors  such  as  a  family  history  of  osteoporosis,  excessive  leanness,  smoking,  excessive  
alcohol  intake  and  poor  nutrition.  (4)  
  
1.9  INVESTIGATION  OF  PATIENTS  WITH  OSTEOPOROSIS  
In  patients  with  fragility  fractures  and/or  osteoporosis,  following  a  history  taking  and  good  
physical  examination,  laboratory  and  radiological  investigations  are  recommended.  Serum  
calcium,  albumin  and  phosphate,  alkaline  phosphatase  and  PTH  levels  are  indicated  in  all  
patients  with   possible   osteoporosis.   (4,13)   The  measurement   of   25-­hydroxyvitamin  D   is  
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indicated   in   certain   scenarios   for   example   in   elderly,   malnourished   or   institutionalized  
patients.   (4)   Hyperparathyroidism   and   osteomalacia   should   be   excluded   as   a   cause   for  
bone  disease.  (4)  Other  secondary  causes  of  osteoporosis  should  be  ruled  out  and  blood  
tests  necessary  for  the  exclusion  of  these  diseases  must  be  done  if  clinically  indicated.  A  
full  blood  count  (FBC),  thyroid  stimulating  hormone  (TSH),  erythrocyte  sedimentation  rate  
(ESR),   serum   creatinine,   protein   electrophoresis,   sex   hormone   levels   and   urine   calcium  
levels   may   be   useful   to   exclude   secondary   causes.   (4)   Radiological   investigations  
appropriate   for   patients  with   osteoporosis   include   standard  X-­rays   and  DEXA  with  BMD  
measurement.   Bone   turnover  markers,   bone  marrow   aspirations   and   bone   biopsies   are  
rarely  done  and  only  if  clinically  indicated.  (4)    
  
In   Africa,   DEXA   scans   are   not   widely   available   and   in   Morocco   for   example,   only   0.6  
DEXA  scans  are  available  per  million  people.  (30)  In  South  Africa  (SA)  a  DEXA  scan  costs  
$130  which   is   relatively  expensive  when   taking   into  account   that   this   is  approximately  a  
third  of  the  monthly  income  of  an  average  person  in  the  country.  (30)    
  
1.10  MANAGEMENT  OF  OSTEOPOROSIS  
Management   of   both   fragility   fractures   and   osteoporosis   is   divided   into   non-­
pharmacological   and   pharmacological   treatment.   Non-­pharmacological   measures   are  
undertaken   to   improve  bone  strength  and  prevent   falls  and   involve  encouraging  physical  
exercise,   limiting  alcohol   intake,  cessation  of  smoking,  adjusting  of  diet  and  avoidance  of  
bone  toxic  drugs.  (4,20)    
  
Nutritional   measures   involve   a   healthy   eating   plan   with   sufficient   protein   and   all   the  
essential   nutrients   including   calcium   and   vitamin   D.   (4,16,20)   High   calcium   intake   has  
been   shown   to   augment   peak   bone  mass   however   the   effect   of   this   is   subject   to   dose,  
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baseline   calcium   intake,   pubertal   maturation   and   genetic   factors.   (4)   Severe   vitamin   D  
deficiency  induces  osteomalacia  and  results  in  an  increase  in  bone  turnover  and  resultant  
osteoporosis.   (4)   Recommended   daily   intake   of   calcium   based   on   SA   osteoporosis  
societies  is  600mg  for  adult  men  and  women  whose  calcium  intake  with  diet  is  insufficient.  
(31)  The  recommended  dosage  of  vitamin  D  is  800-­1200IU  per  day.  (4,31)    
  
A   related   meta-­analysis   showed   only   a   small,   non-­progressive   increase   in   BMD   with  
calcium   supplements.   (32)   Following   these   reviews,   the   United   States   food   and   drug  
administration  suggested  that  an  adequate  calcium  intake  in  the  diet  is  the  most  beneficial  
for  bone  health.  (1,32)  
  
Supplementation  of  20g  of  protein  in  the  diet  of  elderly  patients  with  hip  fractures  has  been  
shown  to  prevent  further  femoral  bone  loss,  lower  mortality  and  shorten  the  hospital  stay.  
(4)  A  high  intake  of  fibre,  oxalate  and  phytate  has  been  shown  to  have  a  negative  effect  on  
intestinal   calcium   absorption.   (4)   High   sodium   intake   also   negatively   impacts   on   the  
calcium  levels  in  the  blood  by  enhancing  the  urinary  excretion  of  calcium.  (4)  Vitamins  C,  
B6,  K,   and  minerals   like   zinc,   copper,   boron   and  manganese   have   also   been   shown   to  
reduce  bone  loss  however  this  needs  to  be  substantiated  with  further  studies.  (4)    
  
Adequate   physical   exercise   is   necessary   for   normal   bone   formation   and   a   sedentary  
lifestyle   contributes   to   rapid   bone   loss.   (1,4)   Regular   weight-­bearing   exercises   such   as  
jogging   and   dancing,   and   muscle-­strengthening   exercises   such   as   yoga,   have   been  
recommended  to  reduce  the  risk  of  falls.  (1,12)  Walking  for  five  kilometers  at  a  brisk  pace  
three  to  four  times  a  week  and  back  strengthening  exercises  have  been  recommended  by  
the  NOFSA  to  improve  hip  and  vertebral  bone  strength  respectively.  (4)  
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The   prevention   of   falls,   especially   in   the   elderly,   is   of   great   importance.   One   in   three  
people  over  the  age  of  65  years  old  fall  once  annually,  and  of  these  falls  five  to  six  percent  
result  in  a  fracture.  (4,16)  In  the  elderly,  risk  factor  tools  have  been  derived  to  predict  the  
occurrence  of  a   fall  and   the  sensitivity  and  specificity  of   these  are   in  excess  of  70%.  (4)  
Institutionalisation,   cognitive   impairment,   gait   and   balance   disorders,   weakness   and  
immobility,   poor   vision,   extrinsic   environmental   hazards,   cardiovascular   disease  
(particularly   orthostasis)   and   medication   side   effects   are   some   of   the   main   risk   factors  
associated  with  falls.  (2,4)    
  
The  cessation  of  smoking  and  a   limitation  of  alcohol   to   less  than  three  units  per  day  are  
also  recommended.  (2,4,12)  A  great  number  of  medications  play  a  role  in  either  reducing  
bone  strength  or  predisposing  to  a  fall.  (4,12)  Examples  of  drugs  that  increase  the  risk  of  
osteoporosis   and   thus   a   future   possible   fragility   fracture   are   glucocorticoids,  
anticonvulsants,  aromatase  inhibitors,  chemotherapeutic  drugs,  immunosuppressants  and  
lithium   to   name   a   few.   (4)   Many   patients,   especially   the   elderly,   are   on   sedatives,  
antidepressants,   antihypertensives   and   hypoglycaemic   agents   that   play   a   pivotal   role   in  
increasing  the  risk  of  falling.  (4)  
  
Pharmacological  agents  that  prevent  bone  loss,  improve  bone  strength  and  reduce  the  risk  
of   future   fractures  are  used  to   treat  osteoporosis  once  confirmed.  (4)   In  addition   to  bone  
modifying   drugs,   analgesia   is   often   prescribed   for   pain   relief.   (25)   Bone   resorption  
inhibitors   include   calcium   and   vitamin   D,   selective   oestrogen   receptor   modulators  
(SERMS),  bisphosphonates  and  oestrogen  and  its  analogues.  (4,12)  Calcitonin  is  a  bone  
resorption  inhibitor  but  is  seldom  used.  (4)  Parathyroid  hormone  and  fluoride  are  used  as  
bone   formation   stimulators   however   fluoride   is   used   infrequently   and   is   currently   not  
recommended   by   the   NOFSA.   (4)   Strontium   ranelate,   anabolic   steroids,   vitamin   D  
  15 
metabolites  and  thiazide  diuretics  are  drugs  with  a  complex  action  on  bone  that  can  also  
be  used  for  osteoporosis  treatment.  (4)    
  
First   line   treatment   in   postmenopausal   women,   in   men,   and   in   certain   secondary  
osteoporosis   are   bisphosphonates.   (4,13,25)   Initial   choice   of   therapy   will   however   be  
dictated  by  the  patients  age,  general  health,  concomitant  disease,  patient  preference  and  
the   clinical   setting.   (4)   There   has   been   a   concern   regarding   the   development   of  
osteonecrosis   of   the   jaw   and   atypical   fractures   in   patients   who   have   been   on  
bisphosphonates.  (4)  However,  the  number  of  patients  with  these  complications  is  small  in  
comparison  with  the  number  of  fractures  that  are  prevented  with  treatment.  (4)    
  
Strontium  ranelate  has  been  registered  in  SA  for  use  in  the  treatment  of  osteoporosis  and  
works   by   both   stimulating   bone   formation   and   inhibiting   bone   resorption   however   it   is  
infrequently  used  due  to  cardiovascular  safety  concerns.  (4)  The  only  drug  that  has  been  
registered   to  stimulate  bone   formation   is   the  synthetic  parathyroid  hormone  Teriparatide.  
(4,33)  Teriparatide  is  only  indicated  in  SA  in  patients  with  two  or  more  fragility  fractures,  in  
patients  who  have  failed  treatment  with  bone  active  medication  and  in  patients  on  chronic  
glucocorticoid   therapy  with   i)  BMD  T-­score  <-­3.5  with  no   fractures   ii)  BMD  T-­score  <-­2.5  
with  one  or  more  fragility  fracture  or  iii)  multiple  fragility  fractures  with  bone  that  cannot  be  
assessed  by  a  DEXA.   (4)  Denosumab   is  an  osteoclast  stimulator   that  has  recently  been  
proposed   as   an   additional   treatment   for   osteoporosis.   (32-­33)   In   SA   Denosumab   is  
currently  not  yet  registered  for  use.  (32)  
  
All   patients   with   fragility   fractures   require   therapy   regardless   of   BMD  measurement.   (4)  
There  are  many  pharmacological  options  for  the  treatment  of  osteoporosis  however  each  
patient  must  be  assessed  individually  to  select  the  most  appropriate  therapy.    
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1.11  MONITORING  OF  THERAPY  
Clinical   evaluation   for   all   patients  with   fragility   fractures  and  osteoporosis  on  medication  
should   be   done   regularly   to   assess   progression   of   disease,   drug   side   effects   and  
adherence   to   therapy.   (4)  Vertebral   imaging   is   recommended  every   four   to   five  years  as  
vertebral  fractures  are  often  asymptomatic.  (4)  Routine  bone  mass  measurements  are  also  
recommended   to   monitor   treatment   and   should   preferably   be   done   using   the   same  
modality,   ideally   a   DEXA   scan.   (1,4)   Currently   there   is   no   consensus   regarding   BMD  
intervals   for   patients   already   on   therapy.   (20)  DEXA   scans   and   serum   calcium   and   25-­
hydroxy  vitamin  D  levels  can  be  done  as  frequently  as  deemed  clinically  necessary.  (13)    
  
If   bisphosphonate   therapy   is   used,   bone   turnover   suppression   can   be   assessed   using  
bone   turnover  markers   such   as   a   urine   N-­telopeptide   level   or   beta-­crosslaps.   (13)   This  
may   serve   as   a   proxy   for   bone   metabolic   activity   however   its   limitation   is   that   it   is  
expensive  and  not  often  clinically   indicated.  (13)  The  continued  need  for  bisphosphonate  
therapy   should   be   assessed   after   four   to   five   years   of   therapy.   (31)   Current   NOFSA  
guidelines   suggest   consideration   of   a   drug   holiday   after   five   years   of   bisphosphonate  
therapy.  (4)    
  
1.12  MORTALITY  AND  MORBIDITY  ASSOCIATED  WITH  OSTEOPOROSIS  
Deaths  due  to  fragility  fractures  associated  with  osteoporosis  are  usually  dependent  on  the  
type  of  fracture,  age,  gender  and  race  of  the  patient.  (34)  Other  systemic  illnesses,  frailty  
and  underlying  comorbidities  may  also  be  contributing  factors  to  mortality  in  these  patients.  
(34)    
  
Mortality   rates  are  highest   in  patients  with   fractures  of   the  vertebrae  and  hip.   (34)   In  hip  
fractures  mortality  rates  are  highest   in   the  first  six  months   immediately  after   the  fracture.  
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(34)  After  a  hip   fracture,  approximately  20%  of  patients  do  not  survive  more   than  a  year  
and  30%  do  not  regain  their  previous  level  of   independence.  (16)  In  the  Middle  East  and  
Africa,   the  mortality   rates   post   hip   fractures   are   predicted   to   be   two   to   three-­fold   higher  
than   in   Western   populations.   (30)   Following   surgery   for   hip   fracture,   postoperative  
complications   include   sepsis   and   the   development   of   cardiovascular   events   such   as  
myocardial  infarctions,  and  these  complications  increase  the  risk  of  mortality  to  90%.  (34)  
Black  women  have  a  higher  mortality  rate  than  white  women  following  a  hip  fracture.  (34)  
Male  patients  post  hip  fracture  had  a  higher  mortality  rate  than  female  patients  regardless  
of  race.  (34)    
  
Vertebral  fractures  are  the  most  frequent  complication  of  osteoporosis  and  are  associated  
with  back  pain,   loss  of  height,  kyphosis,  respiratory  compromise  and  functional  disability.  
(34)  After   the  age  of  50  years,   the   lifetime   risk  of  a  vertebral   fracture   is  9%   in  men  and  
15%  in  women.  (34)  The  prevalence  of  vertebral  deformities  increases  from  5-­10%  percent  
in  women   in   their  50s,   to  45   -­  55%  of   those   in   their  80s.   (34)  Annual  mortality   rates   for  
vertebral  fractures  range  from  1.9-­42%.  (34)  The  most  common  cause  of  death  in  patients  
with   vertebral   fractures   are   pulmonary   causes   such   as   pneumonia   and   restrictive   lung  
disease  and  their  complications.  (34)    
  
Data   is   lacking   regarding  mortality   in   fractures  not  occurring   in   the  hip  or  vertebrae,  and  
long-­term  mortality   risk   following  an  osteoporotic   fracture.  Mortality   rates   for  SA  patients  
are  also  lacking.  
  
1.13  THE  ROLE  OF  THE  ORTHOPAEDIC  SURGEON  
The   clinical   relevance   of   osteoporosis   is   that   it   results   in   fractures.   (18)   Even   fragility  
fractures   that   occur   after   low   impact   trauma   hint   at   an   underlying   compromise   of   bone  
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strength.  Due   to   these   resultant   fractures,   the  orthopaedic  surgeon   is   frequently   the   first  
and  often  the  only  doctor  to  manage  the  patient.  (18)    
  
Most  patients  with  osteoporosis  sustain  fractures  of  the  hip,  vertebrae,  wrist  and  proximal  
humerus  and  of  these,  it  is  frequently  those  with  hip  and  vertebral  fractures  that  are  likely  
to   be   admitted.   (26)   Patients   with   wrist   and   proximal   humerus   fractures   are   usually  
discharged  after  a  very  short  hospital  stay  or  are  not  admitted  at  all  and  are  treated  on  an  
outpatient   basis.   (26)   Orthopaedic   surgeons   thus   have   an   opportunity   to   address   the  
compromise   in   bone   strength   either   by   clinical   assessment   and   further   radiological  
investigations   or   by   appropriate   referral   to   a   physician   or   endocrinologist.   Despite   this,  
orthopaedic  surgeons  often  rely  on  primary  care  providers  to  assess  and  initiate  treatment  
for  underlying  osteoporosis  in  fragility  fractures.  (18)  
  
A   study   done   by   Jadhav   et   al   in   India   involved   16   orthopaedic   doctors   and   45   general  
practitioners   and   compared   their   knowledge   of   fragility   fractures,   risk   factors,  
complications,  prevention  and  management,  between  the  two  sets  of  practitioners.  (18)  A  
questionnaire  with  a   total  of   ten  questions  was  used  for   this  study.   (18)  The  orthopaedic  
surgeons  had  more  knowledge  regarding  fragility  fractures  when  compared  to  the  general  
practitioners.  (18)  This  would  imply  that  while  the  orthopaedic  surgeons  are  largely  relying  
on   general   practitioners   to   further   evaluate   and   treat   these   patients,   these   general  
practitioners  are  neglecting  to  adequately  investigate  and  treat  such  patients  due  to  a  very  
poor   knowledge  of   fragility   fractures.   In   particular,   the   risk   factors   associated  with   these  
fractures  and  the  prevention  thereof  was  especially  lacking.  (18)  
  
One   can   postulate   that   future   fracture   risk   in   these   susceptible   patients   is   not   being  
assessed  and  thus  the  morbidity  and  mortality  of  the  patients  may  increase  with  time.  To  
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add  to  this,  economic  investment  in  these  patients  for  the  future  will  be  significantly  higher  
especially  considering  the  emergency  department  resources  that  will  be  necessary,  cost  of  
future   inpatient   admission,   radiological   investigations,   treatment   and   probably   surgical  
interventions  may  be  required.  (18)  For  the  patients  themselves,  suffering  a  future  fracture  
would   adversely   affect   their   physical   and   psychological   well-­being,   quality   of   life   and  
mortality  rate.  (18)    
  
In   a   survey   of   3422   orthopaedic   surgeons   across   six   countries,   90%   of   them   did   not  
routinely  do  a  BMD  measurement   for  a  patient  with  a  first-­time  fragility   fracture  and  50%  
admitted   to   poor   knowledge   and   having   had   no   formal   training   regarding   osteoporosis.  
(34)  Only  20%  of  the  surgeons  referred  patients  with  a  first-­time  fragility  fracture  for  a  BMD  
measurement.  (35)  
  
Two  similar  studies  were  carried  out   in   Iran  and   the  UK   respectively.  The  study  done   in  
Iran  by  Sorbi  et  al  tested  the  knowledge  of  2021  orthopaedic  surgeons  via  a  questionnaire  
covering  topics  of  diagnosis,   treatment  and  approach  to  a  patient  with  a  fragility  fracture.  
(23)  Less  than  10%  of  those  surveyed  included  BMD  while  evaluating  a  fragility  fracture,  
32%   prescribed   the   correct   dose   of   calcium   and   vitamin   D   and   only   30%   would  
appropriately  refer   if  a   low  impact  trauma  was  suspected.  (23)  This  study  concluded  that  
majority  of   the  orthopaedic  surgeons  had  only   limited  knowledge  with   regards   to   fragility  
fractures   and   the   assessment   of   osteoporosis   in   patients   with   such   fractures.   (23)  
Orthopaedic   surgeons   seem   to   have   a   perception   that   they   are   not   involved   in   care   for  
osteoporosis  and  patients  are  under  investigated  and  often  go  untreated.  (23)    
  
A   British   study   done   in   2007   retrospectively   reviewed   38   patients   who   had   probable  
fragility  fractures  six  months  post   injury  via  a  telephonic  questionnaire  to  assess  whether  
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they  had  been  assessed,  investigated  or  treated  for  osteoporosis.  (26)  The  majority  of  the  
patients   had   never   been   referred   for   investigations   or   to   a   general   practitioner   for  
independent  screening  after   the   first  audit.   (26)  After   initiating  an  awareness  programme  
regarding  recent  guidelines  and  changing  infrastructure  in  the  fracture  clinic,  still  only  50%  
of  patients  were  appropriately  referred.  (26)  
  
Gardner   et   al   retrospectively   analysed   300   randomly   selected   British   patients   with  
fractures  of  the  femoral  neck.  (36)  Only  58  (19.3%)  had  received  a  prescription  for  calcium  
and   vitamin   D   at   the   time   of   their   discharge.   (36)   Of   these   patients,   40   (13.3%   of   the  
overall  group)  had  been  prescribed  calcium  alone,  but  only  18  (6.0%  of  the  overall  group)  
had  received  medication  to  actively  prevent  bone  resorption  and  to  treat  osteoporosis.  (36)  
The   remaining   81%   of   patients   were   discharged   without   osteoporosis   medication   and  
none  had  a  bone  density  scan  while  in  hospital.  (36)  
  
Efforts   to  highlight   the  crucial   role   that  orthopaedic  doctors  play   in   the   role  of   identifying  
patients   at   risk,   referring   them   appropriately   and   initiating   treatment  must   be   continued.  
(26)  Orthopaedic  surgeons  should  be  aware  that  they  play  a  vital  role   in  the  reduction  of  
future  fracture  risk  and  the  associated  complications  in  these  patients.  (26)  
  
The   increasing   life  expectancy   in  countries   in  Africa  and  the  Middle  East  will   result   in  an  
increase   in   the   burden   of   osteoporosis   in   years   to   come.   (30)   It   therefore   becomes  
necessary  to  encourage  identification  and  promote  management  of  osteoporosis  in  these  
populations  to  curb  future  financial  strains  on  health  care.    
  
This  study  was  based  on  several   studies  assessing  various  aspects  of   fragility   fractures  
and   resultant   osteoporosis.   These   studies   surveyed   risk   assessment   for   future   fragility  
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fractures,   (26,37)   referral   for   further   osteoporosis   management   (38)   and   awareness  
amongst   orthopaedic   surgeons   with   regards   to   appropriate   diagnosis   and   referral   of  
patients  with  suspected  osteoporosis.  (18,23)  
  
This  study  was  based  primarily  on  a  study   in  Germany  done  by  Kolios  et  al  who  used  a  
medical   questionnaire   containing   19   questions   for  men  and  21   questions   for   females   to  
quickly   and   effectively   screen   large   numbers   of   patients   for   reduced   BMD.   (39)   In   the  
study  by  Kolios  et  al,  bone  specific   laboratory   investigations  and  DEXA  scans  were  also  
examined  as  diagnostic  instruments  for  osteoporosis  however  no  laboratory  investigations  
or  DEXA  scans  were  done  in  this  study  due  to  time  and  resource  constraints.  (39)    
  
Other   studies   reviewed   include   a   study   by   Gidwani   et   al   who   audited   the   assessment,  
investigation   and   treatment   of   patients   with   fragility   fractures   in   their   hospital   using   a  
telephonic  questionnaire.   (26)  Similarly,  Sugi  et  al  used  a   telephonic   interview   to  survey  
whether   patients   50   years   or   older   with   fragility   fractures   had   been   identified   and  
appropriately  referred.  (38)    
  
It  is  often  thought  by  practitioners  that  patients  with  fragility  fractures  and  osteoporosis  are  
very  elderly  however  this  is  not  always  the  case.  One  in  two  women  and  one  in  five  men  
older  than  the  age  50  years  will  sustain  an  osteoporotic  fracture  in  their  lifetime.  (21,25)  A  
recent  fracture  at  any  major  skeletal  site  in  an  adult  older  than  50  years  of  age  should  be  
considered   a   significant   event   for   the   diagnosis   of   osteoporosis.   (1)   Subjects   aged   50  
years  and  above  were  recruited  for  the  study  based  on  this  and  on  previously  done  similar  
studies   that   recruited   subjects   in   this   age   group.   (18,23,26,38,39)   Low   trauma   fractures  
were  used  as  a  surrogate  for  fragility.    
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In  South  African  hospitals,  trauma  units  are  overburdened  with  a  large  number  of  patients.  
If  a  screening  tool,  that  is  not  time  consuming,  is  available  to  the  orthopaedic  department  
this   may   aid   practitioners   immensely   in   detecting   bone   loss   and   implementing   anti-­
osteoporotic  therapy.  (39)  
  
1.14  AIMS  AND  OBJECTIVES  
AIM  
To   assess   whether   African   subjects   with   fragility   fractures   are   being   identified   for  
assessment  for  osteoporosis  on  presentation  to  the  orthopaedic  department.  
  
OBJECTIVES 
  To  determine   if  orthopaedic  surgeons  question  subjects  with   fragility   fractures  about   risk  
factors  for  osteoporosis.  
  To   assess  whether   orthopaedic   surgeons   educate   subjects  with   fragility   fractures   about  
secondary  prevention.  
  To   ascertain   whether   subjects   were   referred   for   further   assessment   of   underlying   bone  
disease  for  osteoporosis.  
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CHAPTER  2:    SUBJECT  S  AND  METHODS 
The  study  was  conducted  in  the  Orthopaedic  wards,  outpatient  clinic  and  casualty  area  at  
Chris   Hani   Baragwanath   Academic   Hospital   (CHBAH)   in   Soweto,   South   Africa.   The  
CHBAH  is  a  large  hospital  with  2888  beds  of  which  232  beds  are  allocated  to  orthopaedic  




Inclusion  criteria:    
  Subjects  >  50  years  of  age  
  Both  male  and  female  African  subjects  
  Subjects  with  fragility  fractures    
  
Exclusion  criteria:    
  Subjects  with  high  impact  fractures  
  Subjects  who  did  not  consent  to  be  in  the  study  
  
    
Approval  was  obtained  from  the  Human  Research  Ethics  Committee  (HREC)  (Medical)  of  
the  University  of  the  Witwatersrand  (M150261)  (Appendix  1).  An  appendant  to  the  original  
ethics  form  was  approved  by  the  HREC  in  December  2016  (Appendix  2).  
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2.2  METHODS  
This   study   was   conducted   using   two   qualitative   questionnaires,   both   designed   and  
administered  by   the   researcher   to   assess  whether   subjects   had  been  asked  about   their  
risk  for  fragility  fractures,  and  whether  they  had  been  educated  about  prevention  of  future  
fractures   by   the   orthopaedic   surgeons.   Both   questionnaires   were   adapted   from   similar  
published  studies  (26,37,39).    
  
The   first   questionnaire   (Appendix   3)   was   administered   in   a   bedside   interview   with   the  
subjects,  after  written,   informed  consent  (Appendix  4)  was  obtained  and  comprised  of  13  
questions   that   addressed   specific   risk   factors   for   osteoporosis,   patient   education   and  
referral  for  further  management.  Risk  factors  addressed  included  a  history  of  prior  fracture,  
family   history   of   osteoporosis   and   the   use   of   corticosteroids.   Advice   regarding   lifestyle  
choices   detrimental   to   bone   health   were   addressed   in   the   first   questionnaire   including  
smoking,   alcohol   use,   diet,   bone   strengthening   exercises,   cortisone   use   and   the   use   of  
hormone  replacement   therapy.  Lastly  subjects  were  asked   if   they  were  advised  to  return  
for  assessment  for  bone  disease.    
  
A  second  questionnaire   (Appendix  5)  was  administered   telephonically  by   the   researcher  
18  months  after  the  first  interview.  Telephonic  consent  was  obtained  from  all  subjects  prior  
to   the   interview   (Appendix   6).   The   second   questionnaire   specifically   addressed  whether  
orthopaedic   surgeons   had   asked   about   ten   risk   factors   for   osteoporosis.   Questions  
regarding  advice  on  lifestyle  changes  for  bone  health  from  the  first  questionnaire  were  also  
incorporated  into  the  second  questionnaire.  Lastly,  subjects  were  asked  if  they  were  told  to  
return  for  assessment  of  bone  disease.    
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All  completed  questionnaires  were  analysed   for   frequency  of   responses  and  reported  as  
the  number  of  responses  received.  
    
2.3  STATISTICAL  ANALYSIS  
Descriptive   analysis   of   the   data   was   carried   out   as   follows:   categorical   variables   were  
summarised   by   frequency   and   percentage   tabulation,   and   illustrated   by   means   of   bar  
charts.  Continuous  variables  were  summarised  by   the  mean  and  standard  deviation  and  
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CHAPTER  3:  RESULTS  
3.1  SUBJECT  CHARACTERISTICS  
A   total   of   103   subjects   were   identified   as   meeting   inclusion   criteria   during   June   to  
September   2015.   Three   female   subjects   declined   to   participate   and   100   subjects   were  
studied.   All   subjects   recruited   for   the   study   signed   a   consent   form   prior   to   the   first  
interview.  The  majority  of  the  subjects  recruited  were  female  (77/100;;77%).    
  
The  majority  of  the  subjects  recruited  were  from  the  orthopaedic  wards  (89/100;;89%),  far  
fewer   from   the  orthopaedic   clinics  as  screening  proved   to  be  difficult   (11/100;;11%),  and  
none  were  recruited  from  the  casualty  area  of  CHBAH.    
  
The  mean  age  of  male  and  female  subjects  combined  was  63.6  (SD+/-­10)  years.  Majority  







Figure  3.1.1  Percentage  of  subjects  in  each  age  group  
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The  main  mechanism  of  injury  was  falling  while  walking  which  occurred  in  85/100;;85%  of  
the   subjects,   13/100;;13%   of   the   subjects   slipped   on   a   smooth   surface,   one   subject   fell  
while  climbing  out  of  a  vehicle  (1/100;;1%)  and  one  had  no  identifiable  trauma  (1/100;;1%).      
    
Table  3.1.1  Baseline  characteristics  of  the  study  population  including  age,  gender,  
recruitment  site  and  mechanism  of  injury  
	   Males  (n=23)   Females  (n=77)  
Mean  Age  (SD)     61.0 (+/-7.8)  64.4 (+/-10.7)  
STUDY  RECRUITMENT  SITE:     
Orthopaedic  ward  n  (%)   18 (78.3) 71 (92.2) 
Orthopaedic  clinic  n  (%)   5 (21.7) 6 (7.8) 
Casualty  n  (%)   0 (0) 0 (0) 
MECHANISM  OF  INJURY:     
Fell  while  walking  n  (%)   23 (100) 56 (72.7) 
Slipped  on  a  smooth  surface  n  (%)   0 (0) 19 (24.7) 
Fell  while  climbing  out  of  a  car  n  
(%)  
0 (0) 1 (1.3) 
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3.1.1  FEMALE  SUBJECTS  
  
The  majority   of   female   subjects   presented  with   fractures   of   the   femur   including   neck   of  
femur,  intertrochanteric,  proximal  and  distal  femur.  The  number  of  typical  fragility  fractures  
that   occurred   in   female   subjects   of   different   age   groups   is   represented   according   to  
highest  prevalence.  (Figure  3.1.2)  
  
Other   less  prevalent   fractures  noted   in   the   female  subjects  studied   included   fractures  of  
the   patella   (4/77;;5.2%),   olecranon   (2/77;;2.6%),   and   tarsal   bones   (1/77;;1.3%).   These  
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3.1.2  MALE  SUBJECTS  
The  majority  of  male  subjects  also  presented  mainly  with  fractures  of  the  femur  including  
neck   of   femur   and   distal   femur   fractures.   The   number   of   typical   fragility   fractures   that  
occurred   in   male   subjects   of   different   age   groups   was   represented   according   to  





Less  prevalent   fractures   in   the  male  subjects  studied   included   fractures  of   the  vertebrae  
(1/23;;4.3%)  and  tarsal  bones  (2/23;;8.7%).  Figure  3.1.4  compares  femur  fractures,  in  male  
and  female  subjects,  with  fractures  of  the  vertebrae  and  other  less  prevalent  fractures.  
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3.2  QUESTIONNAIRE  RESULTS  
3.2.1  QUESTIONNAIRE  ONE  RESULTS  
A  total  of  (89/100;;89%)  subjects  were  asked  at  least  one  screening  question  about  the  risk  
of  osteoporosis.  The  most  frequently  asked  question  about  risk  factors  for  osteoporosis  in  
the  first  interview,  was  regarding  previous  fractures.  Thirty  seven  percent  (37/100;;37%)  of  
all  subjects  had  been  given  advice  regarding  appropriate  bone  strengthening  exercises  to  
prevent   osteoporosis   in   the   future.   Only   five   subjects   (5/100;;5%)   with   fragility   fractures  
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Table  3.2.1:  Number  of  subjects  asked  questions  regarding  risk  factors,  education  and  





Have  you  been  asked  about  being  diagnosed  with  osteoporosis?   6/100  (6%)  
Have  you  been  asked  about  prior  fractures?     61/100  (61%)  
Have  you  been  given  any  dietary  advice  to  prevent  osteoporosis?     2/100  (2%)  
Have  you  been  advised  to  do  bone  strengthening  and  weight  bearing  
exercises  for  30  minutes  2/3  times  a  week?     37/100  (37%)  
Have  you  been  advised  against  cigarette  smoking?     13/100  (13%)  
Have  you  been  advised  against  excessive  alcohol  intake?     12/100  (12%)  
Have  you  been  put  on  any  calcium  supplements?   2/100  (2%)  
Have  you  been  put  on  any  vitamin  D  supplements?   1/100  (1%)  
Have  you  used  cortisone  before?     2/100  (2%)  
Have  you  been  advised  against  the  use  of  cortisone?     0/100  (0%)  
Do  you  have  a  family  history  of  bone  disease?     2/100  (2%)  
Have  you  been  educated  about  hormone  replacement  therapy  to  
prevent  osteoporosis?   0/100  (0%)  
Have  you  been  advised  to  come  back  to  be  assessed  for  bone  
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3.2.2  QUESTIONNAIRE  TWO  RESULTS  
  
To  determine  if  subjects  had  been  referred  for  investigation  since  discharge,  a  second  
interview  was  conducted  telephonically  in  December  2016.  Only  37  of  the  100  subjects  
(37/100;;37%)  initially  interviewed  could  be  contacted  telephonically.  The  remaining  63  
subjects  (63/100;;63%)  were  not  contacted  because  they  had  either  demised  (3/63;;4.8%),  
they  did  not  have  a  phone  number  (34/63;;54.0%),  the  phone  was  switched  off  
(12/63;;19.0%)  or  the  number  was  incorrect  (14/63;;22.2%).  Of  the  37  subjects,  30  were  
female  (30/37;;81.1%).  The  mean  age  of  the  female  and  male  subjects  interviewed  was  
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Table  3.2.2:  Number  of  subjects  asked  questions  regarding  risk  factors,  education  and  
referral  for  osteoporosis  during  telephonic  interview  
Questions   Number  of  subjects  (n=37)  
Have  you  been  asked  about  being  diagnosed  with  
osteoporosis?   0/37  (0%)  
Have  you  been  asked  about  prior  fractures?     24/37  (64.9%)  
Did  your  doctor  ask  you  if  your  diet  included  dairy  products  
or  calcium  rich  food?   0/37  (0%)  
Have  you  been  given  any  dietary  advice  to  prevent  
osteoporosis?     1/37  (2.7%)  
Did  your  doctor  ask  you  if  you  spend  less  than  10  minutes  
outdoors?     0/37  (0%)  
Have  you  been  advised  to  do  bone  strengthening  and  
weight  bearing  exercises  for  30  minutes  2/3  times  a  day?   18/37  (48.6%)  
Did  your  doctor  ask  you  if  you  are  currently  smoking?     6/37  (16.2%)  
Have  you  been  advised  against  cigarette  smoking?     4/37(10.8%)  
Did  your  doctor  ask  you  if  you  are  drinking  >3  alcoholic  
drinks  per  day?   5/37  (13.5%)  
Have  you  been  advised  against  excessive  alcohol  intake?   4/37  (10.8%)    
Were  you  asked  if  you  were  on  any  calcium  or  vitamin  D  
supplements?     2/37  (5.4%)  
Have  you  been  put  on  any  calcium  supplements?     2/37  (5.4%)  
Have  you  been  put  on  any  vitamin  D  supplements?     2/37  (5.4%)  
Were  you  asked  if  you  had  used  cortisone  before?     0/37  (0%)  
Have  you  been  advised  against  the  use  of  cortisone?     0/37  (0%)  
Were  you  asked  if  you  have  a  family  history  of  bone  
disease?     0/37  (0%)  
If  female,  were  you  asked  if  you  were  postmenopausal?     0/37  (0%)  
Have  you  been  educated  about  hormone  replacement  
therapy  to  prevent  the  development  of  osteoporosis?     0/37  (0%)  
Have  you  since  been  diagnosed  with  osteoporosis  or  been  
advised  to  come  back  to  be  assessed  for  bone  disease?     3/37  (8.1%)  
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Most   subjects  were   asked   the   question   regarding   prior   fractures   and   the  most   frequent  
advice   given   was   still   regarding   bone-­strengthening   exercises.   Only   three   subjects  
(3/37;;8.1%)   stated   that   they   had   been   either   diagnosed   with   osteoporosis   (following   a  
DEXA   scan)   or   advised   to   come   back   for   assessment.   Of   these   three   subjects,   two  
subjects  were  newly  diagnosed  or  referred  for  assessment  (2/37;;5.4%).  Thus,  in  total  after  
both  interviews  had  been  conducted,  only  seven  out  of  the  100  subjects  (7/100;;7%)  were  
appropriately  diagnosed  or  referred  however  none  could  recall  having  had  a  DEXA  scan.  
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CHAPTER  4:  DISCUSSION  
  
Osteoporosis  is  a  silent  disease  usually  presenting  with  pain  related  to  a  fracture  or  loss  of  
height  related  to  vertebral  compression  fractures.  (41)  The  prevalence  of  the  disease,  lack  
of  early  symptoms,  and  availability  of  effective  treatments  make  screening  for  osteoporosis  
critical  to  the  management  of  this  disease.  (41)  
  
In  this  study,  approximately  half  of  the  subjects  were  between  the  ages  of  50  and  60  years  
proving  that  osteoporosis  is  not  a  disease  solely  affecting  the  elderly.  Considering  that  the  
majority   of   subjects   were   below   60   years   old,   it   is   not   surprising   that   the   majority   of  
patients   were   female   since   male   subjects   tend   to   develop   fragility   fractures   and  
osteoporosis  later  in  life.  (5)  
  
Both  genders  presented  mainly  with  hip  or  femur  fractures  and  this  is  in  keeping  with  data  
worldwide  showing  these  to  be  one  of  the  most  prevalent  fragility  fractures  noted.  (1,4,25)  
Surprisingly  only  one  male  subject  presented  with  a  vertebral  fracture  as  this  is  usually  the  
most  prevalent  fragility  fracture  seen  and  these  subjects  often  require  hospital  admission.  
(26,42)  This  may  be  due  to  this  subset  of  patients  being  found  to  be  clinically  stable  and  
not  having  to  undergo  surgery  and  therefore  not  needing  to  be  admitted.  It  is  also  possible  
that  patients  were  discharged  due  to  staff  or  resource  limitations.    
  
Fractures   of   the   radius   and   humerus   were   infrequently   noted   with   only   14   subjects  
identified.  This   is   in  keeping  with  studies  showing   forearm  fractures   to  be  rare   in  African  
subjects  with  osteoporosis.  (2)  However,  other  studies  have  shown  forearm  fractures  to  be  
more  prevalent  in  subjects  over  the  age  of  65  years.  It  can  be  postulated  that  patients  with  
forearm  fractures  were  found  to  be  clinically  stable  and  were  discharged  without  hospital  
admission.   It   is  also  possible   that  such  patients  presented   to  primary  or  secondary  care  
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facilities  for  management  rather  than  to  CHBAH.  According  to  studies  fragility  fractures  of  
the   ankle   and   tibia/fibula   were   much   less   prevalent   than   those   of   the   hip,   spine   and  
forearm.  However,   in   our   study,   up   to   39%  of   females   and  30%  of  men  presented  with  
these   fractures.  The  reason   for   this   is  unknown  and  would  require  a   full  history   from  the  
patient  to  confirm  the  mechanism  of  injury.    
  
In  Denmark,  a  study  done  by  Eiken,  surveyed  56  orthopaedic  departments  throughout  the  
country   to   assess   the   management   of   osteoporotic   patients   with   regards   to   referral   for  
DEXA   scan,   modification   of   lifestyle   risk   factors,   and   treatment   initiation.   (43)   Of   the  
departments  surveyed,  88%  of  them  did  not  refer  patients  with  low  trauma  fractures  for  a  
DEXA   scan.   (43)  Only   50%   of   the   departments  were   educating   their   patients   regarding  
lifestyle   risk   factors.   (43)   In  addition,  only  11%  of   the  departments   initiated   treatment   for  
their  patients  with  calcium  and  vitamin  D.  (43)  These  study  results  are  similar  to  our  study  
results  confirming  suboptimal  management  of  these  patients  by  our  orthopaedic  surgeons.      
  
The  results  of  both  interviews  conducted  via  the  questionnaire  confirmed  that  the  only  risk  
factor   that   was   regularly   identified   by   the   orthopaedic   surgeons   in   the   majority   of   the  
patients  was  a  history  of  prior  fractures.  Prior  fragility  fractures  have  been  identified  as  one  
of   the   most   important   risk   factors   with   which   to   predict   future   fractures   and   thus   this  
information   is   vital   to   plan   treatment   and   prevent   future   fractures.   (44)   However,   this  
particular  risk  factor  may  have  been  relevant  to  the  orthopaedic  surgeon  in  order  to  focus  
their  attention  on  the  surgical  therapy  for  the  subject  rather  than  as  a  screening  question  
for  underlying  osteoporosis.  The  majority  of  orthopaedic  surgeons,  world  over,  focus  their  
attention   on   the   intervention   required   for   the   fracture   rather   than   medical   therapy  
necessary  for  the  prevention  of  future  fractures.  (23,45)    
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In   the   second   interview   it   was   found   that   other   important   risk   factors   such   as   smoking,  
alcohol  use,  poor  diet,  lack  of  exercise  and  the  use  of  cortisone  and  hormone  replacement  
therapy  were  assessed  only  in  32%  of  the  subjects.    
  
The  multinational  survey  reported  on  by  Dreinhofer  et  al  highlighted  the  lack  of  knowledge  
and   confidence   amongst   orthopaedic   surgeons   in   diagnosing   and   treating   osteoporosis.  
(35)  This  is  unfortunate,  as  the  orthopaedic  surgeon  is  often  the  first  and  only  practitioner  
to   attend   to   patients   with   fragility   fractures.   (23)   A   number   of   studies   have   been   done  
showing   the   poor   rates   of   screening   and   subsequent   treatment   in   these   patients.  
Freedman  et  al  reviewed  a  database  of  three  million  patients  with  fragility  fractures  in  30  
different  states  within  the  US  and  found  that  only  24%  of  these  patients  had  had  either  a  
diagnostic  evaluation  or  treatment  for  osteoporosis.  (43)      
  
A  number  of  theories  regarding  the  decline  in  the  diagnosis  and  treatment  of  osteoporosis  
have  been  put  forward.  (46)  A  disregard  for  the  seriousness  of  osteoporotic  fractures  and  
a  decrease  in  the  number  of  DEXA  scans  done,  even  in  private  institutions,  were  factors  
that  may  have  resulted  in  a  decrease  in  disease  identification.  (46)  There  have  also  been  
numerous   concerns   regarding   the   rare   complications   of   bisphosphonates   such   as  
osteonecrosis  of  the  jaw  and  atypical  fragility  fractures.  (46,47)  
  
In  CHBAH,  due  to  the  large  number  of  patients  seen  in  the  orthopaedic  ward  and  clinics,  
there   may   have   been   insufficient   time   and   resources   for   orthopaedic   surgeons   to   fully  
screen  patients  with   low   impact   trauma  for  osteoporosis.   In  addition,   the  need  for  a  high  
patient   turnover   in   the   wards   may   reduce   the   impetus   to   keep   the   patients   longer   for  
further   investigations.   As   such,   after   discharge,   patients   may   be   lost   to   follow   up   or  
referred   to   local   clinics  without   appropriate   investigations.   In   the   orthopaedic  wards   it   is  
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often  the  junior  doctors  who  are  tending  to  these  patients  and  due  to  a  lack  of  knowledge  
or  insight,  investigations  and  treatment  for  osteoporosis  may  be  neglected.    
  
Since  patients  are  unlikely  to  perceive  osteoporosis  as  a  disease  that  results  in  significant  
morbidity  and  mortality,  it  is  therefore  up  to  clinicians  to  educate  the  patient  on  risk  factors  
and   complications   of   the   disease   even   prior   to   discussing   treatment   options.   (41)   Non-­
pharmacological   interventions   regarding   bone-­strengthening   exercises,   cessation   of  
smoking,   reducing  excessive  alcohol   consumption,  diet  and  avoidance  of   corticosteroids  
were   addressed   in   only   44%   of   patients.   Prior   to   discharge,   only   one   new   subject   had  
been  advised  regarding  the  detrimental  effects  of  alcohol  on  bone  health.    
  
In  this  survey,  only  7%  of  the  subjects  were  either  diagnosed  with  osteoporosis  or  referred  
for   further   management   leaving   93%   of   the   subjects   with   no   appropriate   diagnosis   nor  
investigation.  These  numbers  are  on  par  with   international  studies  showing  up  to  95%  of  
patients   discharged  without   determining   a   cause   for   the   fracture.   (23)  Vestergaard   et   al  
published   a   study   in   Denmark   involving   18566   patients   with   fractures   possibly   due   to  
osteoporosis.  Of  these  subjects,  only  0.3%  of  men  and  2.2%  of  females  were  diagnosed  
and   managed   appropriately.   (48)   At   present,   there   are   no   other   similar   SA   studies   to  
compare  our  data  with.    
  
Less   than   5%  of   the   subjects   surveyed  were   asked   about  medication   use,   and   advised  
against   medication   detrimental   to   bone   health.   Only   one   new   subject   was   initiated   on  
vitamin  D  supplementation  following  discharge.    Calcium  and  vitamin  D  supplementation  is  
only  deemed  necessary  if  dietary  intake  is  proven  to  be  insufficient.  (1,31,32)  However  in  
the  second  interview  conducted,  no  subjects  were  assessed  to  determine  if  their  diet  had  
sufficient  calcium.    
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Calcium  and  vitamin  D  have  been  shown  to  be  effective  in  preventing  the  development  of  
osteoporosis  however,   a   clinical   review  by  Murad  et   al   in  patients  with   fragility   fractures  
showed  them  to  be  ineffective  if  given  separately.  (49)  A  combination  of  both  calcium  and  
vitamin  D  at  recommended  doses  of  1200mg  and  800mg  respectively  was  found  to  reduce  
the  risk  of  future  fractures  by  improving  bone  strength.  (49)  Only  four  subjects  in  our  study  
were  adequately  treated  following  their  fracture.    
  
Studies  have  shown   that  orthopaedic  surgeons  were  unable   to  extract  a  detailed  history  
from  patients  regarding  risk  factors,  comorbidities  or  medications  due  to  time  constraints.  
(38)  The  “own  the  bone”  initiative  by  the  American  orthopaedic  association  thus  proposed  
the   establishment   of   a   multidisciplinary   team   to   adequately   care   for   those   with  
osteoporosis.  (38)  A  combined  medical  effort  with  various  practitioners  was  deemed  more  
beneficial.    
  
Orthopaedic   surgeons   agree   that   they   should   expand   their   role   in   the   medical  
management  of  osteoporosis,  however  many  believe   that  general  practitioners  would  be  
more   suited   to   manage   these   patients.   (23,43)   If   treatment   were   to   be   initiated   by   the  
orthopaedic   surgeons   it   is   relatively   simple,   a   yearly   infusion   of   zoledronate   5mg   given  
within   90   days   significantly   reduces   the   risk   of   vertebral   and   non-­vertebral   fractures   in  
patients  with  an  average  age  of  74.5  years  and  a  recent  hip  fracture.  (25)  A  study  done  by  
Edwards  et  al  showed  that   the  effect  of   immediate   treatment   for  osteoporosis   in  patients  
presenting  with  fragility  fractures,  usually  carried  out  by  orthopaedic  surgeons,  was  much  
superior   than  delayed  treatment  by  general  practitioners.   (38)  General  practitioners  have  
cited  cost,  a  lack  of  available  guidelines  and  an  inability  to  keep  up  to  date  with  new  data,  
as  reasons  for  often  missing  the  diagnosis  of  osteoporosis.  (43)  An  uncertainty  regarding  
medication  has  also  resulted  in  inappropriate  treatment  for  the  disease.  (43)    
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Fragility  fractures  increase  societal  burdens  in  terms  of  mortality,  quality  of  life,  as  well  as  
economic   costs.   (49)   The   combined   annual   cost   of   all   osteoporotic   fractures   has   been  
estimated  to  be  $20  billion  in  the  US  and  €30  billion  in  the  European  Union.  (49,50)  In  SA,  
currently   minimal   data   exists   regarding   incidence   of   disease   or   cost   involved   for   all  
osteoporotic  fractures.  As  such,  identification  of  osteoporosis  in  relevant  patients  becomes  
of  paramount  importance  to  prevent  increased  mortality  and  morbidity  and  to  decrease  the  
resultant  economic  burden.  (51)  
  
Guided   by   the   NOF   and   the   International   Osteoporosis   Foundation   (IOF),   a   Fracture  
Liaison  Service  (FLS)  was  proposed  to  encourage  a  multidisciplinary  approach  to  patients  
admitted  to  hospitals,  clinics  and  emergency  rooms  with  osteoporotic  fractures  to  prevent  
future   fractures.   (47,51)  These  patients,  once   identified,  would  be   incorporated   into  well-­
developed  osteoporosis  treatment  and  management  plans.  (47)  Use  of  the  FLS  was  found  
to  improve  quality  of  care  and  reduce  the  rate  of  subsequent  fracture.  (41)    
  
In  SA,   funding   for  a  designated  professional   to   screen   for  osteoporosis   in  each  hospital  
and   clinic   may   be   difficult   due   to   the   financial   constraints   for   medical   care   in   this  
developing   country,   where   HIV   and   Tuberculosis   dominate   the   budget.   However,   if   the  
estimated  annual  cost  and  mortality  rate  is  considered,  the  long-­term  benefits  of  a  fracture  
intervention  programme  are  unquestionable.    
  
A  study  done  by  Sewell  et  al  in  the  UK  monitored  patients  with  fragility  fractures  admitted  
to  a  fracture  clinic.  (52)  Initially,  a  mere  33%  of  the  patients  surveyed  were  appropriately  
managed   for   secondary   prevention   of   fractures.   (52)   Thereafter   a   fragility   fracture  
prevention  strategy  was  implemented  consisting  of  fracture  clinic  infrastructure  changes,  a  
staff   awareness   teaching   programme   and   the   assignment   of   an   osteoporosis   nurse  
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specialist.   (52)  After  six  months,  new  patients  with   fragility   fractures  were  evaluated  and  
88%  of  them  had  been  appropriately  managed  for  secondary  prevention.  (52)  This  study  
demonstrates  viable  changes  that  can  possibly  be  considered  for  the  SA  setting.    
  
A   cost-­effective   method   of   screening   patients   in   SA   may   also   be   for   the   orthopaedic  
doctors  to  use  a  simple  questionnaire  such  as  the  one  used  in  this  study,  on  all  patients  
with   low   trauma   fractures  who  present   to   them.  Junior  doctors  or  qualified  nurses   in   the  
orthopaedic   department   would   find   this   screening   process   simple   and  would   require   no  
more   than   ten   minutes   to   interview   their   patient.   If   risk   factors   are   identified,   lifestyle  
modifications  can  be  encouraged,  a  DEXA  scan  can  be  booked  if  required  and  treatment  
for   osteoporosis   can   be   initiated.   Gosch   et   al   published   an   algorithm   in   2013   for  
orthopaedic  surgeons  to  use  to  make  assessment  easier  and  less  time  consuming.  (47)  
  
In  SA   risk   factors  and  BMD  measurements  specific   to  our  unique  population  need   to  be  
investigated   further.   BMD   criteria   on  DEXA   scan   to   diagnose   osteoporosis   needs   to   be  
confirmed  in  our  ethnically  diverse  population.    
  
The   crucial   role   of   orthopaedic   surgeons   in   referring   patients   with   fragility   fractures   is  
highlighted  by  this  survey.  The  detection  and  appropriate  referral  of  such  patients  should  
primarily  be  the  responsibility  of  the  orthopaedic  surgeon.  The  interpretation  of  scans  and  
prescription  of  medication  can  however  be  done  by  other  practitioners  such  as  a  general  
physician,  endocrinologist,   rheumatologist  or  geriatrician   if  necessary.   (26)   In  SA,  due   to  
financial   constraints,   many   patients   find   it   difficult   to   frequent   health   care   facilities   for  
regular  assessments.  In  light  of  this,  optimal  care  for  the  patient  should  ideally  be  initiated  
on  presentation  to  the  hospital  with  a  fragility  fracture.    
  
  42 
Educational   opportunities   need   to   be  established   for   orthopaedic   surgeons   to   tackle   the  
limitations   in   knowledge   of   osteoporosis   assessment   and   treatment.   (18)   Postgraduate  
training   should   also   encompass   effective   screening   and   secondary   prevention   of  
osteoporosis.  (18)  
  
Unfortunately,   there   were   a   number   of   limitations   to   the   study   done.   Subjects   were  
recruited   for   the   study   if   they   had   a   low   trauma   fractures   however   not   all   the   subjects  
recruited   had   traditional   fragility   fractures.   Fractures   of   the   olecranon,   patella   and   tarsal  
bones  were  included  in  the  study  on  the  basis  of  the  mechanism  of  injury  noted  in  the  file.  
The   criteria   for   recruitment   into   the   study   should   ideally   have   been   improved   with  
additional  information.    
  
The  limitation  regarding  the  questionnaires  was  that  they  were  both  adapted  from  similar  
studies   that   have   been   published,   but   they   were   not   piloted,   nor   were   any   validated  
scoring   tools  used  which  would  have  obviated   the  need   to  pilot   the  questionnaires.  The  
first  questionnaire  contained  questions  that  were  not  accurate  and  as  such  were  unable  to  
achieve   the   main   objective   of   the   study.   Following   this,   a   second   questionnaire   was  
devised  in  order  to  more  accurately  answer  the  initial  research  question  posed.  Only  37  of  
the   original   100   patients   could   be   contacted   and   interviewed   and   this   was   done  
approximately  18  months  after  the  first  interview.  This  resulted  in  a  much  smaller  number  
of  patients  that  could  be  assessed  appropriately.    
  
During   both   interviews,   great   care   was   taken   to   enable   the   patient   to   understand   the  
questions  posed.  However,  despite  this,  subjects  may  have  misinterpreted  the  questions.  
This   could   be   due   to   language   barriers   or   due   to   a   lack   of   insight   and   understanding.  
Questions   may   have   been   ambiguous   inciting   inaccurate   responses.   Furthermore,  
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subjects   often   could   not   understand   the   difference   between   standard  X-­rays   and  DEXA  
scans  when  asked  if  they  had  been  diagnosed  with  osteoporosis  or  given  follow  up  dates  
for   assessment   thereof.   Therefore,   the   accuracy   of   the   data   regarding   the   assessment  
following   their   fragility   fracture   is   questionable   and   the   number   of   patients   assessed  
appropriately  is  likely  to  be  even  lower.  
  
The  strength  of  this  study  is  that  it  identified  a  lack  of  adequate  assessment  and  follow  up  
of  patients  with  fragility  fractures  in  CHBAH.  This  highlights  the  need  for  further  education  
of  orthopaedic  service  practitioners  in  order  to  initiate  risk  factor  modification  and  treatment  
as  well  as  to  improve  access  to  follow  up  care  for  these  subjects.    
  
CHBAH   is   one   of   the   largest   hospitals   in   the   world   with   a   very   busy   orthopaedic   unit.  
Turnover   rates   of   patients   in   the  orthopaedic  ward  at  CHBAH  are  high  and  orthopaedic  
clinics  are  held  almost  daily  thus  making  it  relatively  easy  to  acquire  the  large  number  of  
subjects  needed  for  the  study.  This  study  looked  at  the  assessment  of  fragility  fractures  in  
African  patients  alone,  which  has  not  been  done  in  prior  research  studies.  Very  little  data  
is  available  on  bone  disease   in  African  patients  and  reference  ranges   for   this  population  
are  still  to  be  determined  for  DEXA  scans.  More  studies  assessing  African  patients  will  be  
necessary  to  better  understand  and  subsequently  manage  these  patients.  This  study  will  
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5.  CONCLUSION  
  
It  is  vitally  important  that  patients  with  fragility  fractures  be  identified  as  potentially  having  
underlying   bone   disease   and   be   referred   appropriately   for   further   investigation   and  
management.  Osteoporotic  fractures  are  largely  preventable  as  environmental  risk  factors  
can   be   altered   and   pharmacological   therapy   is   readily   available   for   treatment   thereof.  
(53,54)   The   prevention   of   future   fractures   should   be   made   a   priority   and   orthopaedic  
surgeons   are   often   the   only   practitioners   with   an   opportunity   to   do   so.   While   a  
multidisciplinary  approach  would  be  ideal  for  patients  with  fragility  fractures,  if  they  are  not  
appropriately  identified  as  having  risk  factors  for  osteoporosis  by  orthopaedic  surgeons  on  
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APPENDIX  3:    QUESTIONNAIRE  ONE  
  
  
QUESTIONS:	   	  	  	  YES	   NO	   UNSURE	  
Have  you  been  asked  about  being  diagnosed  with  
osteoporosis?  
   
Have  you  been  asked  about  prior  fractures?      
Have  you  been  given  any  dietary  advice  to  prevent  
osteoporosis?    
   
Have  you  been  advised  to  do  bone  strengthening  and  
weight  bearing  exercises  for  30  minutes  2/3  times  a  week?    
   
Have  you  been  advised  against  cigarette  smoking?      
Have  you  been  advised  against  excessive  alcohol  intake?        
Have  you  been  put  on  any  calcium  supplements?        
Have  you  been  put  on  any  Vit  D  supplements?        
Have  you  used  cortisone  before?      
Have  you  been  advised  against  the  use  of  cortisone?        
Do  you  have  a  family  history  of  bone  disease?      
Have  you  been  educated  about  hormone  replacement  
therapy  to  prevent  the  development  of  osteoporosis?    
   
Have  you  been  advised  to  come  back  to  be  assessed  for  
bone  disease?    
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  I  hereby  confirm  that  I  have  been  informed  by  the  study  doctor,  Dr.  P.M.Thomas  about  the  
nature,  conduct,  benefits  and  risks  of  the  clinical  study:  Assessment  of  patients  with  fragility  
fractures  in  the  Orthopaedic  setting  at  Chris  Hani  Baragwanath  Academic  Hospital.  
  I   have   also   received,   read   and   understood   the   above   written   information   (Participant  
information  leaflet  and  Informed  consent)  regarding  the  clinical  study.  
  I  am  aware  that  the  results  of  the  study,  including  personal  details  regarding  my  sex,  age,  
date  of  birth,  initials  and  diagnosis  will  be  anonymously  processed  into  the  study  report.  
  In  view  of  the  requirements  of  research,  I  agree  that  data  collected  during  this  study  can  be  
processed  in  a  computerized  system  by  Dr.  P.M.Thomas  or  on  their  behalf.    
  I  may,  at  any  stage,  without  prejudice,  withdraw  my  consent  and  participation  in  the  study.  
  I  have  had  sufficient  opportunity  to  ask  questions  and  (of  my  own  free  will)  declare  myself  




Printed  Name  Signature/Thumbprint  Date  and  time  
  
I,  Dr.P.M.Thomas,  herewith  confirm  that  the  above  participant  has  been  fully  informed  about  the  




Printed  Name  Signature  Date  and  time  
  
  
TRANSLATOR/OTHER  PERSON  EXPLAINING  INFORMED  CONSENT_____________________  
(DESIGNATION):  
  




Printed  Name  Signature  Date  and  time  
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VERBAL  PARTICIPANT  INFORMED  CONSENT:  
  
    I,   the   undersigned,   Dr.P.M.Thomas   have   read   and   have   explained   fully   to   the  
participant,   named   ........................………………………….   and/or   his/her  
relative/friend/legal  representative,  the  participant  information  leaflet.    
    The   account   I   have   given   has   explained   both   the   possible   risks   and   benefits   of   the  
study  as  well  as  the  alternative  treatments  available  for  his/her  illness.  The  participant  
and/or  his/her  relative/friend/legal  representative  understands  these.  
    The  participant  and/or  his/her   relative/friend/legal   representative   indicated   that  he/she  
understands  that  the  participant  will  be  free  to  withdraw  from  the  study  at  any  time  for  
any  reason  and  without  jeopardising  his/her  subsequent  treatment.      
  
I   hereby   certify   that,   the   participant   and/or   his/her   relative/friend/legal   representative,  




Printed  Name  Signature/Thumbprint  Date  and  time  
  
I,  Dr.P.M.Thomas,  herewith  confirm  that  the  above  participant  has  been  fully  informed  




Printed  Name  Signature  Date  and  time  
  










Printed  Name  Signature  Date  and  time  
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APPENDIX  5:  QUESTIONNAIRE  TWO  
QUESTIONS:	   YES	   	  NO	   UNSURE	  
Have  you  been  asked  about  being  diagnosed  with  
osteoporosis?  
   
Have  you  been  asked  about  prior  fractures?      
Did  your  doctor  ask  you  if  your  diet  included  dairy  products  
or  calcium  rich  food?    
   
Have  you  been  given  any  dietary  advice  to  prevent  
osteoporosis?    
   
Did  your  doctor  ask  you  if  you  spend  less  than  10  minutes  
outdoors?    
   
Have  you  been  advised  to  do  bone  strengthening  and  
weight  bearing  exercises  for  30  minutes  2/3  times  a  week?    
   
Did  your  doctor  ask  you  if  you  are  currently  smoking?      
Have  you  been  advised  against  cigarette  smoking?      
Did  your  doctor  ask  you  if  you  are  drinking  >3  alcoholic  
drinks  per  day?    
   
Have  you  been  advised  against  excessive  alcohol  intake?        
Were  you  asked  if  you  were  on  any  calcium  or  Vitamin  D  
supplements?  
   
Have  you  been  put  on  any  calcium  supplements?        
Have  you  been  put  on  any  Vit  D  supplements?        
Have  you  used  cortisone  before?      
Have  you  been  advised  against  the  use  of  cortisone?        
Were  you  asked  if  you  have  a  family  history  of  bone  
disease?  
   
If  female,  were  you  asked  if  you  were  postmenopausal?        
Have  you  been  educated  about  hormone  replacement  
therapy  to  prevent  the  development  of  osteoporosis?    
   
Have  you  since  been  diagnosed  with  osteoporosis  or  been  
advised  to  come  back  to  be  assessed  for  bone  disease?    
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APPENDIX  6:  TELEPHONIC  CONSENT  FORM  
  
TELEPHONIC  CONSENT  FORM  	  
Good  day  Mr/Miss/Mrs….,  my  name   is  Dr.  Preetha  Thomas.   I  am  a  medical  doctor.  We  
first  spoke  when  you  were   treated   for  a   fracture   in   the  Orthopaedic  ward  or  clinic  at   the  
Chris  Hani  Baragwanath  Academic  Hospital  in  June  or  July  of  2015.  Do  I  have  the  correct  
person?  At  that  time,  I  was  doing  research  to  find  out   if  you  had  been  questioned  by  the  
orthopaedic   doctor   about   risk   factors   for   fracturing   your   bone   after   very   minimal   injury,  
otherwise   called   a   fragility   fracture.   I   also   wanted   to   know   if   you   had   been   referred   for  
further  bone  strength   testing.  The  title  of  my  study   is   ‘Assessment  of   fragility   fractures   in  
African  patients  in  the  Orthopaedic  setting  at  Chris  Hani  Baragwanath  Academic  Hospital’.  
  
Unfortunately,   the   questions   that   I   asked   you   at   that   time   did   not   give   me   enough  
information  to  complete  my  research.  This  is  the  reason  for  my  call  today.    
  
If  you  have  about  10  minutes,  I’d  like  to  ask  a  few  more  questions  that  will  help  me  know  if  
you   have   since   then   been   assessed   as   having   a   risk   factor   for   fragility   fractures   and  
osteoporosis,   and   referred   to   a   doctor   to   have   the   strength   of   your   bones   tested,  
specifically  a  DEXA  scan.  
  
Only   ‘Yes’   or   ‘No’   answers  will   be   required.   Being   part   of   this   study   is   completely   your  
choice   and   you   may   refuse   to   participate   at   any   time.   There   is   no   compensation   for  
responding   nor   is   there   any   known   risk.   All   your   personal   information   will   be   kept  
confidential.   Just  as  with   the   first   interview.   I  have  permission   from   the  University  of   the  
Witwatersrand  Human  Research  Ethics  Committee  (HREC).    
    





Thank  you  for  your  time,  I  appreciate  your  help  in  this  regard.  	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If  you  would  like  any  further  information  regarding  your  rights  as  a  research  participant,  or  
you  have  any  complaints  regarding  this  research  study  please  feel  free  to  contact  me  on  
0721725387,  or  alternatively  you  may  contact  the  Human  Research  Ethics  committee  
(HREC)  at  the  University  of  Witwatersrand  at  (011)  717  2301.	  	  	  
  59 








2017  corrections  done.pdf  







FILE:	 PREETHA_THOMAS_702377_2017  CORRECTIONSDONE.PDF  
(1.21M)    
TIME  SUBMITTED:  09-­FEB-­2017  12:20PM    
SUBMISSION  ID:  768680634 
WORD  COUNT  14242    
CHARACTER  COUNT  78164   
  
Please  see  document  ‘Turnitin’  on  this  CD  for  the  complete  Turnitin  report.    
  60 
	  
  
  
  
 
